Please login to the form below

Not currently logged in
Email:
Password:

Crescendo Biologics appoints CFO

Theodora Harold joins the drug discovery firm

Crescendo Biologics Theodora HaroldCambridge, UK-based Crescendo Biologics has appointed Theodora Harold as its new chief financial officer.

Harold brings 20 years of pharmaceutical and corporate finance industry experience to the role, with particular expertise in growing and early stage biotech companies.

She joins from PsiOxus Therapeutics where she served as chief financial officer, and has also held a number of positions at Cytomyx Holdings, OrthoMimetics, and Mission Therapeutics.

Dr Peter Pack, chief executive officer of Crescendo Biologics, said: “Theo's appointment as Crescendo's new chief financial officer places us in an excellent position to drive ahead with our ambitious plans to create a high value pipeline of differentiated Humabody therapeutics for treating cancer indications with substantial unmet need.

“The experience that she brings to Crescendo strengthens the existing management team and is crucial in allowing us to continue building both strategic and financial value in the company.”

1st November 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics